A new systematic review and meta-analysis reveals that JAK inhibitors offer a safe and effective treatment approach for acute severe ulcerative colitis, showing strong clinical response rates and low colectomy rates across short- and long-term follow-up periods for patients who fail standard therapies.
Acute severe ulcerative colitis is a life-threatening complication of inflammatory bowel disease characterized by systemic toxicity, including fever, severe anemia, elevated inflammatory markers, and frequent bloody stools as defined by the Truelove and Witts criteria. Without prompt medical intervention or surgical management, patients face severe risks such as toxic dilation of the colon, hemorrhage, or sepsis. Standard initial management relies on intravenous corticosteroids, yet roughly 20% of patients fail to respond adequately and require surgical removal of the colon.
Evaluating JAK Inhibitors for Acute Severe Ulcerative Colitis
When standard rescue therapies like infliximab or cyclosporine fall short or present limiting factors, clinicians often navigate difficult treatment decisions. Janus kinase inhibitors, including tofacitinib and upadacitinib, are approved for ulcerative colitis patients who experience an inadequate response to biologics, but their use for acute severe ulcerative colitis remains off-label. To evaluate their real-world utility, researchers analyzed 35 studies encompassing 664 patients across major literature databases, representing 19 studies on tofacitinib, 15 on upadacitinib, and one study examining both agents.
The investigation highlights why these medications are drawing attention in complex clinical algorithms. As Dr.
“Because patients with ASUC are excluded from licensing trials, the evidence on the efficacy and safety of JAK inhibitors will be pertinent in management algorithms.”
Dr. Anuraag Jena, MD, Institute of Medical Sciences and SUM Hospital
Comparing Clinical Response Rates Across Tofacitinib and Upadacitinib
The meta-analysis tracked pooled clinical response rates, remission rates, and colectomy outcomes across three distinct timeframes: short-term under one month, intermediate-term under three months, and long-term ranging from three to 12 months. The data demonstrates measurable differences in how patients respond to each agent during initial rescue phases versus sustained maintenance.
| Therapy and Timeframe | Pooled Clinical Response | Remission Rate | Colectomy Rate |
|---|---|---|---|
| Tofacitinib (<1 month) | 77.9% | Not reported | 11.5% |
| Upadacitinib (<1 month) | 86.5% | Not reported | 11.2% |
| Tofacitinib (3 months) | 57.2% | 37.3% | 16.1% |
| Upadacitinib (3 months) | 56.1% | 47.4% | 21.2% |
| Tofacitinib (3–12 months) | 41.4% | 33.8% | 22.6% |
| Upadacitinib (3–12 months) | 35.1% | 37.5% | 23.4% |
While upadacitinib may be more potent than tofacitinib for the induction of clinical remission in moderate to severe UC, the pooled outcomes between the two drugs remained broadly similar specifically within the acute severe ulcerative colitis setting. Furthermore, when evaluating tofacitinib dosing strategies, researchers found no difference in efficacy when comparing high-dose regimens against standard-dose regimens.
Safety Profiles and Adverse Events in Salvage Therapy
Deploying advanced immunosuppressive medications during severe disease flares requires careful monitoring of potential complications. According to the systematic review, the most frequently observed adverse event was acne, affecting 12.9% of patients. General infections occurred in 8.8% of cases, with herpes zoster accounting for 3.4%. Lipid abnormalities were documented in 6.3% of patients, while venous thromboembolism occurred in 2.2% and major adverse cardiovascular events were recorded in 0.7% of patients.
These safety outcomes factor heavily into ongoing discussions regarding optimal sequencing for salvage therapies. Traditional options like infliximab face challenges due to interactions with the inflamed gastrointestinal tract and the increased metabolic activity seen in ASUC, which can compromise drug clearance and long-term efficacy. Early diagnostic workups—including blood tests for inflammatory markers, stool evaluations for pathogens like Clostridioides difficile, and sigmoidoscopy with biopsy to rule out cytomegalovirus infection—remain essential before initiating advanced rescue treatments.
Ultimately, the review concludes that JAK inhibitors are promising and effective options in the management of patients with ASUC with good rates of clinical response and remission and low colectomy rates at short- (<1 month), intermediate- (<3 months), and long-term (3-12 months) follow-up, providing clinicians with vital data to guide future therapeutic protocols.
По теме
